Ultrasound-based phenotyping distinguishes inflammatory and non-inflammatory forms of difficult-to-treat psoriatic arthritis, ...

With new systemic treatments now available for psoriatic disease, questions remain on the comparable efficacy and safety of these therapies.

As second-line therapy for PsA and axSpA, no clear treatment-retention benefit at 3 years was seen when swapping to a bDMARD with another MOA.

With the right guidance, you can adapt and keep doing the things you love. One of the most effective tools in that journey is ...

Lp(a) is a genetic lipid particle that, according to new data from the Family Heart Foundation, can significantly increases ...